Merck posts better-than-expected second-quarter results on Keytruda strength

Merck reported higher-than-expected second-quarter sales on Tuesday and raised its full-year revenue forecast on the strength of its top-selling cancer treatment Keytruda.

本文内容来自外部来源，点击「继续访问」将跳转到原始发布站点。